Trial Profile

Intravitreal Injection of Lucentis (Ranibizumab) after Pars Plana Vitrectomy and Subretinal Application of Recombinant Tissue Plasminogen Activator (rtPA) in Patients with Acute Submacular Hemorrhage as Complication of Exsudative Age-related Macular Degeneration (AMD).[ Intravitreale Lucentisinjektion (Ranibizumab) nach pars plana Vitrektomie und subretinaler Applikation von recombinant tissue plasminogen activator (rtPA) bei akuter submakulärer Blutung als Komplikation der exsudativen altersabhängigen Makuladegeneration (AMD).]

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 28 May 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

02 Mar 2016 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
12 Feb 2014 New source identified and integrated.German Clinical Trials Register (DRKS)
06 Jan 2014 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com